Corrine Savill is Chief Business Officer of Cullinan Oncology, Inc.. Currently has a direct ownership of 203,490 shares of CGEM, which is worth approximately $2.56 Million. The most recent transaction as insider was on Feb 22, 2024, when has been sold 37,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 203K
0% 3M change
19.62% 12M change
Total Value Held $2.56 Million

Corrine Savill Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 22 2024
BUY
Grant, award, or other acquisition
-
37,500 Added 15.56%
203,490 Common Stock
Feb 01 2024
SELL
Open market or private sale
$647,200 $16.18 p/Share
40,000 Reduced 19.42%
165,990 Common Stock
Feb 01 2024
BUY
Exercise of conversion of derivative security
$172,000 $4.3 p/Share
40,000 Added 16.26%
205,990 Common Stock
Jan 29 2024
SELL
Open market or private sale
$563,600 $14.09 p/Share
40,000 Reduced 19.42%
165,990 Common Stock
Jan 29 2024
BUY
Exercise of conversion of derivative security
$172,000 $4.3 p/Share
40,000 Added 16.26%
205,990 Common Stock
Jan 23 2024
SELL
Open market or private sale
$265,597 $12.46 p/Share
21,316 Reduced 11.38%
165,990 Common Stock
Jan 23 2024
BUY
Exercise of conversion of derivative security
$91,658 $4.3 p/Share
21,316 Added 10.22%
187,306 Common Stock
Jan 22 2024
SELL
Open market or private sale
$226,076 $12.1 p/Share
18,684 Reduced 10.12%
165,990 Common Stock
Jan 22 2024
BUY
Exercise of conversion of derivative security
$62,603 $4.3 p/Share
14,559 Added 7.31%
184,674 Common Stock
Feb 17 2023
BUY
Grant, award, or other acquisition
-
20,500 Added 10.75%
170,115 Common Stock
Jul 19 2022
SELL
Open market or private sale
$227,661 $15.22 p/Share
14,958 Reduced 9.09%
149,615 Common Stock
Jul 18 2022
SELL
Open market or private sale
$75,933 $15.06 p/Share
5,042 Reduced 2.97%
164,573 Common Stock
Jul 11 2022
SELL
Open market or private sale
$543,600 $13.59 p/Share
40,000 Reduced 19.08%
169,615 Common Stock
Feb 11 2022
BUY
Grant, award, or other acquisition
-
16,500 Added 7.3%
209,615 Common Stock
CS

Corrine Savill

Chief Business Officer
Cambridge, MA

Track Institutional and Insider Activities on CGEM

Follow Cullinan Oncology, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CGEM shares.

Notify only if

Insider Trading

Get notified when an Cullinan Oncology, Inc. insider buys or sells CGEM shares.

Notify only if

News

Receive news related to Cullinan Oncology, Inc.

Track Activities on CGEM